Search Results | Blood | American Society of Hematology

1-20 of 104383

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

Blood (2022) 140 (Supplement 2): LBA-4.

DOI: https://doi.org/10.1182/blood-2022-171463

Published: 2022

Journal Articles

Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III Apply-PNH Study

Blood (2022) 140 (Supplement 2): LBA-2.

DOI: https://doi.org/10.1182/blood-2022-171469

Published: 2022

Journal Articles

Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study

Blood (2022) 140 (Supplement 2): LBA-6.

DOI: https://doi.org/10.1182/blood-2022-171538

Published: 2022

Journal Articles

Low-Molecular-Weight Heparin Versus Standard Pregnancy Care for Women with Recurrent Miscarriage and Inherited Thrombophilia (ALIFE2): An Open-Label, Phase III Randomized Controlled Trial

Siobhan Quenby, Katie Booth, Louise Hiller, Arri Coomarasamy, Eva Hamulyák, Luuk Scheres, Paulien G. de Jong, Thijs van Haaps, Lauren J. Ewington, Shreeya Tewary, Mariëtte Goddijn, Saskia Middeldorp

Blood (2022) 140 (Supplement 2): LBA-5.

DOI: https://doi.org/10.1182/blood-2022-171707

Published: 2022

Journal Articles

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Blood (2022) 140 (Supplement 2): LBA-3.

DOI: https://doi.org/10.1182/blood-2022-171733

Published: 2022

Journal Articles

Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial

Blood (2022) 140 (Supplement 2): LBA-1.

DOI: https://doi.org/10.1182/blood-2022-171751

Published: 2022

Journal Articles

Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 2267–2269.

DOI: https://doi.org/10.1182/blood-2022-162892

Published: 2022

Journal Articles

Epigenetic Age Acceleration and Neurocognitive Function Among Long-Term Survivors of Pediatric Hodgkin Lymphoma: A Report from the St. Jude Lifetime Cohort

AnnaLynn M Williams, Qian Dong, Nicholas S. Phillips, Matt J. Ehrhardt, Deokumar Srivastava, Sedigheh Mirzaei Salehabadi, Yutaka Yasui, Kirsten K. Ness, Melissa M. Hudson, Leslie L. Robison, Kevin R. Krull, Zhaoming Wang

Blood (2022) 140 (Supplement 1): 2181–2182.

DOI: https://doi.org/10.1182/blood-2022-159026

Published: 2022

Journal Articles

The Impact of Cumulative Anesthesia Exposure on Neurocognitive Outcomes in Children with High-Risk Precursor B Acute Lymphoblastic Leukemia: A Multicenter Children's Oncology Group Study

Sarah Alexander, Sumit Gupta, John Kairalla, Emily Hibbitts, Hannah Weisman, Doralina Anghelescu, Naomi J Winick, Kevin R. Krull, Wanda L Salzer, Michael J. Burke, Lia Gore, Meenakshi Devidas, Stephen P. Hunger, Mignon L. Loh, Kristina Hardy

Blood (2022) 140 (Supplement 1): 2179–2180.

DOI: https://doi.org/10.1182/blood-2022-166765

Published: 2022

Journal Articles

Self-Efficacy and Stigma in Adults with Sickle Cell Disease: An Import Study Analysis

Stephanie H Guarino, Keshab Subedi, Olusegun Bakare, Charmaine Wright, Lee Pachter, Mary Catherine Beach, Sophie M. Lanzkron

Blood (2022) 140 (Supplement 1): 2177–2178.

DOI: https://doi.org/10.1182/blood-2022-163718

Published: 2022

Journal Articles

Identification and Successful Targeting of a Larger Than Expected Health Literacy Gap in Young People with Sickle Cell Disease Transitioning from Pediatric to Adult Care

S. Helen Oram, Daniel Dexter, Jumoke Okikiolu, Honor Nicholl, Jack Kerwin, Joshua Kader, Bethan Williams, Arvind Nagra

Blood (2022) 140 (Supplement 1): 2175–2176.

DOI: https://doi.org/10.1182/blood-2022-162275

Published: 2022

Journal Articles

Barriers to Transition from Pediatric to Adult Care in Adolescents and Young Adults with Sickle Cell Disease: A Mixed-Method Study on the Impact of Systems of Inequity

Kemar V. Prussien, Haley L. Faust, Kim Smith-Whitley, Lamia P. Barakat, Lisa A. Schwartz

Blood (2022) 140 (Supplement 1): 2173–2174.

DOI: https://doi.org/10.1182/blood-2022-159007

Published: 2022

Journal Articles

Systematically Interrogating Downstream Regulation Mechanisms of HOXA9 in MLL-r Leukemia Via Functional Noncoding CRISPR Screens

Chunliang Li, Shaela Wright, Xuijie Zhao, Shelby Mryncza, Beisi Xu

Blood (2022) 140 (Supplement 1): 1269–1270.

DOI: https://doi.org/10.1182/blood-2022-159186

Published: 2022

Journal Articles

Isatuximab Plus Carfilzomib and Dexamethasone in Patients with Early Versus Late Relapsed Multiple Myeloma: Ikema Subgroup Analysis

Thierry Facon, Philippe Moreau, Ross Baker, Ludek Pour, Chang-Ki Min, Xavier Leleu, Mohamad Mohty, Lionel Karlin, Andreea Rawlings, Christina Tekle, Sandrine Schwab, Marie-Laure Risse, Thomas Martin

Blood (2022) 140 (Supplement 1): 1820–1822.

DOI: https://doi.org/10.1182/blood-2022-159105

Published: 2022

Journal Articles

Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma

Carlyn Tan, David Nemirovsky, Andriy Derkach, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Urvi A Shah, Dhwani Patel, Kylee H Maclachlan, Oscar B Lahoud, Gunjan L. Shah, Michael Scordo, David J. Chung, Heather Landau, Sergio A Giralt, Alexander M Lesokhin, Neha Korde, Saad Usmani

Blood (2022) 140 (Supplement 1): 1817–1819.

DOI: https://doi.org/10.1182/blood-2022-169161

Published: 2022

Journal Articles

Bortezomib-Melphalan-Prednisone (VMP) Vs. Lenalidomide-Dexamethasone (Rd) in Transplant-Ineligible Real-Life Multiple Myeloma Patients: Updated Results of the Randomized Phase IV Real MM Trial

Blood (2022) 140 (Supplement 1): 1814–1816.

DOI: https://doi.org/10.1182/blood-2022-162178

Published: 2022

Journal Articles

Total Metabolic Tumor Volume Is Confirmed As Independent Prognostic Factor in Treatment Naïve Follicular Lymphoma Patients and Can be Combined with FLIPI2 to Improve Prognostic Accuracy. a FOLL12 Substudy By the Fondazione Italiana Linfomi

Blood (2022) 140 (Supplement 1): 1313–1315.

DOI: https://doi.org/10.1182/blood-2022-166225

Published: 2022

Journal Articles

Relapse Timing Is Associated with Distinct Evolutionary Dynamics and Response to Salvage Therapy in DLBCL

Blood (2022) 140 (Supplement 1): 1310–1312.

DOI: https://doi.org/10.1182/blood-2022-160187

Published: 2022

Journal Articles

EBV Dictates Lower Tumor Neoepitopes Scores and Intra-Tumoral Repertoire Diversity in NHL from Immuno-Compromized Patients

Marine Baron, Karim Labreche, Amira Bouzidi, Marianne Veyri, Nathalie Désiré, Véronique Leblond, Florence Coulet, Pierre-Yves Boelle, Fatou Seck Thiam, Damien Roos-Weil, Frédéric Charlotte, Frederic Davi, Elsa Poullot, Alice Rousseau, Corinne Haioun, Jean-Philippe Spano, Brigitte Autran, Choquet Sylvain, Amélie Guihot

Blood (2022) 140 (Supplement 1): 758–759.

DOI: https://doi.org/10.1182/blood-2022-162321

Published: 2022

Journal Articles

Durable Clinical Impacts and Mechanisms of Action and Resistance in EZH1/2-Targeting Epigenetic Therapy

Blood (2022) 140 (Supplement 1): 756–757.

DOI: https://doi.org/10.1182/blood-2022-159275

Published: 2022

2 3 4 5

NARROW

Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study

Low-Molecular-Weight Heparin Versus Standard Pregnancy Care for Women with Recurrent Miscarriage and Inherited Thrombophilia (ALIFE2): An Open-Label, Phase III Randomized Controlled Trial

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial

Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia

Epigenetic Age Acceleration and Neurocognitive Function Among Long-Term Survivors of Pediatric Hodgkin Lymphoma: A Report from the St. Jude Lifetime Cohort

The Impact of Cumulative Anesthesia Exposure on Neurocognitive Outcomes in Children with High-Risk Precursor B Acute Lymphoblastic Leukemia: A Multicenter Children's Oncology Group Study

Self-Efficacy and Stigma in Adults with Sickle Cell Disease: An Import Study Analysis

Identification and Successful Targeting of a Larger Than Expected Health Literacy Gap in Young People with Sickle Cell Disease Transitioning from Pediatric to Adult Care

Barriers to Transition from Pediatric to Adult Care in Adolescents and Young Adults with Sickle Cell Disease: A Mixed-Method Study on the Impact of Systems of Inequity

Systematically Interrogating Downstream Regulation Mechanisms of HOXA9 in MLL-r Leukemia Via Functional Noncoding CRISPR Screens

Isatuximab Plus Carfilzomib and Dexamethasone in Patients with Early Versus Late Relapsed Multiple Myeloma: Ikema Subgroup Analysis

Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma

Bortezomib-Melphalan-Prednisone (VMP) Vs. Lenalidomide-Dexamethasone (Rd) in Transplant-Ineligible Real-Life Multiple Myeloma Patients: Updated Results of the Randomized Phase IV Real MM Trial

Total Metabolic Tumor Volume Is Confirmed As Independent Prognostic Factor in Treatment Naïve Follicular Lymphoma Patients and Can be Combined with FLIPI2 to Improve Prognostic Accuracy. a FOLL12 Substudy By the Fondazione Italiana Linfomi

Relapse Timing Is Associated with Distinct Evolutionary Dynamics and Response to Salvage Therapy in DLBCL

EBV Dictates Lower Tumor Neoepitopes Scores and Intra-Tumoral Repertoire Diversity in NHL from Immuno-Compromized Patients

Durable Clinical Impacts and Mechanisms of Action and Resistance in EZH1/2-Targeting Epigenetic Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only